Long-term real-world outcomes of nivolumab+ipilimumab treatment of unresectable pleural mesothelioma: update of Meso-Immune GFPC 04-2021 study

November 3, 2026 | Comments Off on Long-term real-world outcomes of nivolumab+ipilimumab treatment of unresectable pleural mesothelioma: update of Meso-Immune GFPC 04-2021 study

Lung Cancer 2026 November [Link] Jean-Baptiste Assié, Laurent Greillier, Aurelien Gobert, Lionel Falchero, Lise Thibonnier, Matthieu Chasseray, Christine Raynaud, Hugo Picchi, Thierry Chatellier, Romain Corre, Olivier Molinier, Alain Bakebe, Charles…

Pre-treatment Tumor Volume Growth Rate and Baseline Volume Measured by an Artificial Intelligence Program Predict Overall Survival in Patients With Pleural Mesothelioma Undergoing Deferred Systemic Therapy

November 2, 2026 | Comments Off on Pre-treatment Tumor Volume Growth Rate and Baseline Volume Measured by an Artificial Intelligence Program Predict Overall Survival in Patients With Pleural Mesothelioma Undergoing Deferred Systemic Therapy

JTO Clinical and Research Reports 2026 June 30 [Link] Illaa Smesseim, Valerio Pugliese, Jacobus Burgers, Kevin Groot Lipman Abstract Introduction: The optimal timing of systemic therapy in pleural mesothelioma remains…

Multi-omics integration in malignant pleural mesothelioma: from molecular evolution and immune ecosystems to precision therapy

October 30, 2026 | Comments Off on Multi-omics integration in malignant pleural mesothelioma: from molecular evolution and immune ecosystems to precision therapy

Frontiers in Oncology 2026 August 13 [Link] Hongmei Li, Kunzhong Zhou, Ruiting Xu, Weifang Wang, Tingting Song, Yonghong Zhou, Jing Ren, Zhiyong Wang, Yiteng Liang, Yilin Chen, Saurav Poudel, Junxuan…

Thonzonium bromide suppresses malignant phenotypes of pleural mesothelioma cells in association with reduced KAP1 Ser473 phosphorylation

October 29, 2026 | Comments Off on Thonzonium bromide suppresses malignant phenotypes of pleural mesothelioma cells in association with reduced KAP1 Ser473 phosphorylation

Tissue & Cell 2026 August 22 [Link] Dan Song, Jintao He, Qianwen Du, Shaoyang Huang, Wenbing Huang, Zhengliang Li, Zifeng Ruan, Xingguo Liu, Jing Zhang, Wei Xiong Abstract Objective: Pleural…

Asbestos mineral fibre exposure significantly affects volatile organic compound profiles of mesothelial cell lines in vitro

October 28, 2026 | Comments Off on Asbestos mineral fibre exposure significantly affects volatile organic compound profiles of mesothelial cell lines in vitro

Scientific Reports 2026 August 29 [Link] Sam Bonsall, Theo Issitt, Nick Peake, Mari Herigstad, Jason Webber, Sarah Haywood-Small Abstract Malignant mesothelioma (MM) is a rare cancer caused by exposure to…

Prognostic Factors and Survival in Pericardial Mesothelioma: A Systematic Review and Quantitative Analysis

October 27, 2026 | Comments Off on Prognostic Factors and Survival in Pericardial Mesothelioma: A Systematic Review and Quantitative Analysis

Cancers 2026 August 11 [Link] Michał Kapałka, Estera Pazek, Michał Krawiec, Michał Sikorski, Grzegorz Hirnle, Tomasz Hrapkowicz Abstract Background: Primary pericardial mesothelioma (PPM) is a rare and aggressive tumor. We…

Sex-Specific Patterns of Asbestos Exposure and Prognostic Biomarkers in Surgically Treated Pleural Mesothelioma: A Retrospective Cohort Study

October 26, 2026 | Comments Off on Sex-Specific Patterns of Asbestos Exposure and Prognostic Biomarkers in Surgically Treated Pleural Mesothelioma: A Retrospective Cohort Study

Cancers 2026 August 14 [Link] Nicolas Pinzon, Shubham Gulati, Andrew Del Re, Emanuela Taioli, Raja Flores, Andrea S Wolf, Stephanie Tuminello Abstract Background/objectives: Sex-based differences in asbestos exposure and tumor…

Prognostic Factors in Patients with Peritoneal Mesothelioma Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Systematic Review and Meta-Analysis

October 16, 2026 | Comments Off on Prognostic Factors in Patients with Peritoneal Mesothelioma Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Systematic Review and Meta-Analysis

Annals of Surgical Oncology 2026 August 25 [Link] Jan Philipp Ramspott, Anna Kolmhofer, Ibrahim Büdeyri, Michael Weitzendorfer, Stephan Regenbogen, Lukas Schabl-Cayron, Philipp Schredl, Alexander D Bungert, Klaus Emmanuel, Dino Bekric,…

Identification of disulfidptosis-related molecular subtypes in pleural mesothelioma demonstrates a correlation with the immune infiltration, prognosis and therapy efficacy

October 15, 2026 | Comments Off on Identification of disulfidptosis-related molecular subtypes in pleural mesothelioma demonstrates a correlation with the immune infiltration, prognosis and therapy efficacy

Discover Oncology 2026 July 25 [Link] Jing Ding, Xuefeng Huang, Wenxiu Yao, Tongyu Lin Abstract Background: Pleural mesothelioma (PM) is a rare and aggressive malignancy with increasing incidence, high mortality,…

Haemophagocytic Lymphohistiocytosis Following Ipilimumab and Nivolumab in Malignant Pleural Mesothelioma: A Case Report

October 14, 2026 | Comments Off on Haemophagocytic Lymphohistiocytosis Following Ipilimumab and Nivolumab in Malignant Pleural Mesothelioma: A Case Report

Cureus 2026 July 16 [Link] Cho May Than, Maung Moe, Ye Win, Kyaw Maung Abstract Haemophagocytic lymphohistiocytosis (HLH) is a rare but potentially fatal hyperinflammatory syndrome caused by dysregulated immune…

Categories